Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients

(2013) MH Kristensen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy

(2012) André B. P. van Kuilenburg et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

(2011) Maurice C. van Staveren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation

(2011) E. Giorgio et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding

(2011) Sabine Weidensee et al.   CLINICAL BIOCHEMISTRY

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

(2010) Joana Savva-Bordalo et al.   BMC CANCER

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

(2010) Chen Guang Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment

(2009) Ursula Amstutz et al.   PHARMACOGENOMICS

A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells

(2009) Alfonso M Lostia et al.   THERAPEUTIC DRUG MONITORING

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

(2008) Ursula Amstutz et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene

(2008) A. B. P. van Kuilenburg et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil

(2008) R. Ben Fredj et al.   PATHOLOGIE BIOLOGIE